Top

Published in:

01-02-2012 | Short Communication

Genome-scale methylation analysis of Parkinson's disease patients' brains reveals DNA hypomethylation and increased mRNA expression of cytochrome P450 2E1

Authors: Oliver Kaut, Ina Schmitt, Ullrich Wüllner

Published in: Neurogenetics | Issue 1/2012

Abstract

Multiple lines of evidence suggest a link between environmental toxins and Parkinson's disease (PD). Although numerous studies reported associations of genetic variants in de-toxifying enzymes, i.e. cytochrome genes, with PD. Epigenetic modifications of genes and subsequent altered expression may confer a yet unappreciated level of susceptibility. We present a genome-wide methylation analysis of PD with quantitative DNA methylation levels of 27.500 CpG sites representing 14.495 genes. We found decreased methylation of the cytochrome P450 2E1 gene and increased expression of CYP2E1 messenger RNA in PD patients' brains, suggesting that epigenetic variants of this cytochrome contribute to PD susceptibility.

Available only for authorised users

Ramocki MB, Zoghbi HY (2008) Failure of neuronal homeostasis results in common neuropsychiatric phenotypes. Nature 455:912–918PubMedCrossRef

Urdinguio RG, Sanchez-Mut JV, Esteller M (2009) Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies. Lancet Neurol 8:1056–1072PubMedCrossRef

Suzuki MM, Bird A (2008) DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet 9:465–476PubMedCrossRef

Jowaed A, Schmitt I, Kaut O, Wüllner U (2010) Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains. J Neurosci 30:6355–6359PubMedCrossRef

Siegmund KD, Connor CM, Campan M, Long TI, Weisenberger DJ, Biniszkiewicz D, Jaenisch R, Laird PW, Akbarian S (2007) DNA methylation in the human cerebral cortex is dynamically regulated throughout the life span and involves differentiated neurons. PLoS One 2:e895PubMedCrossRef

Braak H, Müller CM, Rüb U, Ackermann H, Bratzke H, de Vos RA, Del Tredici K (2006) Pathology associated with sporadic Parkinson's disease-where does it end? J Neural Transm Suppl 70:89–97PubMedCrossRef

Soutto M, Peng D, Razvi M, Ruemmele P, Hartmann A, Roessner A, Schneider-Stock R, El-Rifai W (2010) Epigenetic and genetic silencing of CHFR in esophageal adenocarcinomas. Cancer 116:4033–4042PubMedCrossRef

Kohlgraf KG, Pingel LC, Dietrich DE, Brogden KA (2010) Defensins as anti-inflammatory compounds and mucosal adjuvants. Future Microbiol 5:99–113PubMedCrossRef

Riedl AG, Watts PM, Jenner P, Marsden CD (1998) P450 enzymes and Parkinson's disease: the story so far. Mov Disord 13:212–220PubMedCrossRef

10.

Shahabi HN, Westberg L, Melke J, Håkansson A, Belin AC, Sydow O, Olson L, Holmberg B, Nissbrandt H (2009) Cytochrome P450 2E1 gene polymorphisms/haplotypes and Parkinson's disease in a Swedish population. J Neural Transm 116:567–573PubMedCrossRef

11.

Kessova I, Cederbaum AI (2003) CYP2E1: biochemistry, toxicology, regulation and function in ethanol-induced liver injury. Curr Mol Med 3:509–518PubMedCrossRef

12.

Watts PM, Riedl AG, Douek DC, Edwards RJ, Boobis AR, Jenner P, Marsden CD (1998) Co-localization of P450 enzymes in the rat substantia nigra with tyrosine hydroxylase. Neuroscience 86:511–519PubMedCrossRef

13.

Howard LA, Miksys S, Hoffmann E, Mash D, Tyndale RF (2003) Brain CYP2E1 is induced by nicotine and ethanol in rat and is higher in smokers and alcoholics. Br J Pharmacol 138(7):1376–1386PubMedCrossRef

14.

Shahabi HN, Andersson DR, Nissbrandt H (2008) Cytochrome P450 2E1 in the substantia nigra: relevance for dopaminergic neurotransmission and free radical production. Synapse 62:379–388PubMedCrossRef

15.

Viaggi C, Vaglini F, Pardini C, Caramelli A, Corsini GU (2009) MPTP-induced model of Parkinson's disease in cytochrome P450 2E1 knockout mice. Neuropharmacology 56:1075–1081PubMedCrossRef

16.

Feinberg AP (2007) Phenotypic plasticity and the epigenetics of human disease. Nature 447:433–440PubMedCrossRef

17.

Maunakea AK, Nagarajan RP, Bilenky M et al (2010) Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature 466:253–257PubMedCrossRef

Title: Genome-scale methylation analysis of Parkinson's disease patients' brains reveals DNA hypomethylation and increased mRNA expression of cytochrome P450 2E1
Authors: Oliver Kaut
Ina Schmitt
Ullrich Wüllner
Publication date: 01-02-2012
Publisher: Springer-Verlag
Published in: Neurogenetics / Issue 1/2012
Print ISSN: 1364-6745
Electronic ISSN: 1364-6753
DOI: https://doi.org/10.1007/s10048-011-0308-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Genome-scale methylation analysis of Parkinson's disease patients' brains reveals DNA hypomethylation and increased mRNA expression of cytochrome P450 2E1

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2012

New brain-specific beta-synuclein isoforms show expression ratio changes in Lewy body diseases

Distinct DNA binding and transcriptional repression characteristics related to different ARX mutations

Independent replication of STAT3 association with multiple sclerosis risk in a large German case–control sample

Vincristine exacerbates asymptomatic Charcot–Marie–Tooth disease with a novel EGR2 mutation

Genotype–phenotype correlation in interstitial 6q deletions: a report of 12 new cases

Pathomechanistic characterization of two exonic L1CAM variants located in trans in an obligate carrier of X-linked hydrocephalus